These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24950059)

  • 21. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
    Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
    PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
    Zhang X; Wang Y; Chiang HC; Hsieh YP; Lu C; Park BH; Jatoi I; Jin VX; Hu Y; Li R
    Breast Cancer Res; 2019 Apr; 21(1):51. PubMed ID: 30995943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
    Cochran RL; Cidado J; Kim M; Zabransky DJ; Croessmann S; Chu D; Wong HY; Beaver JA; Cravero K; Erlanger B; Parsons H; Heaphy CM; Meeker AK; Lauring J; Park BH
    Oncotarget; 2015 Sep; 6(28):25240-51. PubMed ID: 26246475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
    Smith NL; Welcsh P; Press JZ; Agnew KJ; Garcia R; Swisher EM
    Genes Chromosomes Cancer; 2012 Nov; 51(11):1054-62. PubMed ID: 22887716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
    Rajan JV; Marquis ST; Gardner HP; Chodosh LA
    Dev Biol; 1997 Apr; 184(2):385-401. PubMed ID: 9133444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
    Catucci I; Verderio P; Pizzamiglio S; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Ripamonti CB; Pasini B; Barile M; Viel A; Giannini G; Papi L; Varesco L; Martayan A; Riboni M; Volorio S; Radice P; Peterlongo P
    Breast Cancer Res Treat; 2011 Feb; 125(3):855-60. PubMed ID: 20652397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage.
    Nieuwenhuis B; Van Assen-Bolt AJ; Van Waarde-Verhagen MA; Sijmons RH; Van der Hout AH; Bauch T; Streffer C; Kampinga HH
    Int J Radiat Biol; 2002 Apr; 78(4):285-95. PubMed ID: 12020440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
    Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history.
    Bisgin A; Boga I; Yalav O; Sonmezler O; Tug Bozdogan S
    Breast J; 2019 Sep; 25(5):1029-1033. PubMed ID: 31228304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
    Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
    Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.